Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPSV23 Immune Response in Late Adolescents with Asthma
NCT02719379Phase 1Completed
- Start
- Apr 2016
- Primary completion
- Jun 2017
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease. Primary endpoint: Change in asthma Control Status at 1 year. Started Apr 2016; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT02719379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02719379.